Vygon Acquires Macatt Medica

With this acquisition, Macatt Medica will become a fully owned subsidiary; boosting Vygon’s presence in South America. Its 21 employees will be joining Vygon’s staff.

Vygon, a specialist single-use medical devices group, today announces the acquisition of Macatt Medica, a distribution company located in Lima, Peru.

The company distributes the majority of Vygon’s products in Peru, including a wide range of enteral nutrition products. The financial terms of the agreement have not been disclosed.

With this acquisition, Macatt Medica will become a fully owned subsidiary; boosting Vygon’s presence in South America. Its 21 employees will be joining Vygon’s staff.

“We are delighted that Macatt is joining the extended Vygon family and, in particular, that this will enable us to strengthen our presence on the market for active medical devices,” said Michel Hanania, vice president for the Latin America region at Vygon.

Hanania added, “This product range will complement the one that we have developed alongside our branch in Colombia, in the area of single-use ‘consumable’ products, which will enable us to offer a comprehensive range of products to our South American client base.”

“It’s a big step forward for Macatt to become Vygon’s Peru subsidiary; we are already working closely, distributing its products; this takeover is a natural progression for our company,” said Manuel Catalan, CEO of Macatt Medica. “This acquisition is an opportunity for Macatt to boost its presence on the distribution market for enteral nutrition products, while at the same time becoming part of a group which shares the same values as us.”

Founded in 1997, Macatt Medica has been distributing Vygon products since 2010. Its turnover rose to €1.7 million ($1.9M) in 2021.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.